Lung imaging system earns FDA nod
The FDA has cleared Optical Coherence Tomography Imaging System (OCTIS), a bronchoscopically-based imaging system for pulmonology from Tomophase.

OCTIS is comprised of a single-use disposable optical catheter and imaging console. Initially, OCTIS will be deployed for tissue imaging of airways and lungs, followed by diagnostic and therapeutic applications, according to Burlington, Mass.-based Tomophase.

The company indicated that the system has the potential to be used to monitor patients with early lung cancer, such as those identified by CT screening, by imaging pulmonary tissue following a CT scan using laser light rather than radiation.